Skip to content

Edgewise Therapeutics, Inc. EWTX Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$81K+3.8%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$122K0.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$16K+45.5%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1K0.0%
Scholar Rock logo
Scholar RockSRRK
$119K+25.3%
Cytokinetics logo
CytokineticsCYTK

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.18B+61.3%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockValue.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Edgewise Therapeutics, Inc. (EWTX) reported common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively of $10K in Q1 2026.
How has Edgewise Therapeutics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively changed year-over-year?
Edgewise Therapeutics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively increased by 11.1% year-over-year, from $9K to $10K.
What is the long-term trend for Edgewise Therapeutics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively?
Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively has grown at a 18.9% compound annual growth rate (CAGR), from $5K to $10K.
What does common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively mean?
This represents the par value of the common shares issued and outstanding. It is a foundational component of shareholders' equity and reflects the legal capital contributed by shareholders. While often small in dollar terms, it tracks the number of shares issued and the company's basic ownership structure.